The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Challenges in targeting KRASG12C mutations
Adrian Sacher, MD, Princess Margaret Cancer Centre, Toronto, Canada, talks on the challenges in targeting KRADG12C. A predominant challenge faced is that compared to other drugs, such as tyrosine kinase inhibitors (TKIs), current response rates with KRASG12C inhibitors are limited. In regard to the novel KRASG12C inhibitor, GDC-6036, combination strategies are under development to optimize clinical efficacy whilst maintaining safety and tolerability. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
